On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

Abstract Background Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC); however, predictive biomarkers with translational relevance...

Full description

Bibliographic Details
Main Authors: Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joon Jeong, Joohyuk Sohn
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Breast Cancer Research
Subjects:
Advanced breast cancer
CDK4/6 inhibitor
Neutrophil-to-lymphocyte ratio
Palbociclib
Online Access:https://doi.org/10.1186/s13058-022-01601-4

Internet

https://doi.org/10.1186/s13058-022-01601-4

Similar Items